Nishiwaki Hiroshi, Ito Mikako, Hamaguchi Tomonari, Maeda Tetsuya, Kashihara Kenichi, Tsuboi Yoshio, Ueyama Jun, Yoshida Takumi, Hanada Hiroyuki, Takeuchi Ichiro, Katsuno Masahisa, Hirayama Masaaki, Ohno Kinji
Division of Neurogenetics, Center for Neurological Diseases and Cancer, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Division of Neurology and Gerontology, Department of Internal Medicine, School of Medicine, Iwate Medical University, Iwate, Japan.
NPJ Parkinsons Dis. 2022 Jun 1;8(1):65. doi: 10.1038/s41531-022-00328-5.
To elucidate the relevance of gut dysbiosis in Parkinson's disease (PD) in disease progression, we made random forest models to predict the progression of PD in two years by gut microbiota in 165 PD patients. The area under the receiver operating characteristic curves (AUROCs) of gut microbiota-based models for Hoehn & Yahr (HY) stages 1 and 2 were 0.799 and 0.705, respectively. Similarly, gut microbiota predicted the progression of Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) III scores in an early stage of PD with AUROC = 0.728. Decreases of short-chain fatty acid-producing genera, Fusicatenibacter, Faecalibacterium, and Blautia, as well as an increase of mucin-degrading genus Akkermansia, predicted accelerated disease progression. The four genera remained unchanged in two years in PD, indicating that the taxonomic changes were not the consequences of disease progression. PD patients with marked gut dysbiosis may thus be destined to progress faster than those without gut dysbiosis.
为了阐明肠道微生物群失调在帕金森病(PD)疾病进展中的相关性,我们建立了随机森林模型,通过165例PD患者的肠道微生物群来预测两年内PD的进展情况。基于肠道微生物群的模型对Hoehn & Yahr(HY)1期和2期的受试者工作特征曲线下面积(AUROC)分别为0.799和0.705。同样,肠道微生物群在PD早期预测运动障碍协会统一帕金森病评定量表(MDS-UPDRS)III评分的进展,AUROC = 0.728。产生短链脂肪酸的菌属(如具核梭杆菌、粪杆菌和布劳特氏菌)减少,以及降解粘蛋白的菌属阿克曼氏菌增加,预示着疾病进展加速。这四个菌属在PD患者中两年内保持不变,表明分类学变化不是疾病进展的结果。因此,肠道微生物群明显失调的PD患者可能比没有肠道微生物群失调的患者注定进展得更快。